- Home
- ERJ vs RARE Comparison
ERJ vs RARE Comparison
Compare ERJ & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERJ
- RARE
- Stock Information
- Founded
- ERJ 1969
- RARE 2010
- Country
- ERJ Brazil
- RARE United States
- Employees
- ERJ N/A
- RARE N/A
- Industry
- ERJ Aerospace
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- ERJ Industrials
- RARE Health Care
- Exchange
- ERJ Nasdaq
- RARE Nasdaq
- Market Cap
- ERJ 6.2B
- RARE 5.2B
- IPO Year
- ERJ 2000
- RARE 2014
- Fundamental
- Price
- ERJ $37.90
- RARE $44.75
- Analyst Decision
- ERJ Buy
- RARE Strong Buy
- Analyst Count
- ERJ 7
- RARE 14
- Target Price
- ERJ $34.86
- RARE $86.79
- AVG Volume (30 Days)
- ERJ 1.3M
- RARE 900.1K
- Earning Date
- ERJ 11-08-2024
- RARE 11-05-2024
- Dividend Yield
- ERJ N/A
- RARE N/A
- EPS Growth
- ERJ N/A
- RARE N/A
- EPS
- ERJ 0.65
- RARE N/A
- Revenue
- ERJ $5,768,274,641.00
- RARE $522,745,000.00
- Revenue This Year
- ERJ N/A
- RARE $27.29
- Revenue Next Year
- ERJ $15.34
- RARE $18.30
- P/E Ratio
- ERJ $14.77
- RARE N/A
- Revenue Growth
- ERJ 17.03
- RARE 27.44
- 52 Week Low
- ERJ $16.02
- RARE $37.02
- 52 Week High
- ERJ $39.46
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- ERJ 60.33
- RARE 23.47
- Support Level
- ERJ $36.83
- RARE $47.73
- Resistance Level
- ERJ $39.46
- RARE $53.04
- Average True Range (ATR)
- ERJ 1.07
- RARE 2.00
- MACD
- ERJ 0.40
- RARE -0.57
- Stochastic Oscillator
- ERJ 75.63
- RARE 2.46
About ERJ Embraer S.A.
Embraer SA based in Sao Paulo, Brazil, manufacturer of jets. Its focus is to achieve customer satisfaction with and services addressing the commercial airline, executive jets, and defense and security markets. It has developed a customer-centric technology-driven portfolio of commercial aviation products and services that allows it to build long-term relationships with clients in the commercial aviation, executive jets, and defense and security markets. It operates through the following segments: Commercial Aviation; Defense and Security, Executive Aviation, Service and Support, and Other Segments. The company generates maximum revenue from the Commercial Aviation segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.